Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis

Xiao-Wei NIU1, Jing-Jing ZHANG2, Ming BAI3, Yu PENG3, Zheng ZHANG3
1The First Clinical Medical School, Lanzhou University, Lanzhou, China
2Baiyin Second People's Hospital, Baiyin, China
3Department of Cardiology, the First Hospital of Lanzhou University, Lanzhou, China

Abstract

Background Suboptimal myocardial reperfusion is common in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Furthermore, it results in increased infarct size and mortality rates. We performed a meta-analysis to evaluate the role of aspiration thrombectomy (AT) combined with intracoronary administration of glycoprotein IIb/IIIa inhibitors (GPI) in the improvement of myocardial reperfusion and clinical outcomes.

Methods PubMed, Embase, Web of Science, and CENTRAL databases were searched for randomized controlled trials (RCTs) investigating combined AT and intracoronary GPI treatment versus AT alone. Outcomes of interest were thrombolysis in myocardial infarction myocardial perfusion grade (TMPG), infarct size (IS) assessed by cardiac magnetic resonance imaging, left ventricular ejection fraction (LVEF), major adverse cardiac events (MACE) at short-term (≤ 1 month) and long-term (6–12 months) follow-up, and bleeding complications during the hospital stay.

Results Eight trials involving 923 patients were included. Compared with AT alone, combined AT and intracoronary GPI significantly increased TMPG 3 flow (RR: 1.15, 95% CI: 1.04 to 1.26), reduced IS [mean difference (MD): −3.46, 95% CI: −5.18 to −1.73], and improved LVEF (MD: 1.44, 95% CI: 0.54 to 2.33). Furthermore, GPI use decreased the risk of MACE at long-term follow-up (RR: 0.60, 95% CI: 0.37 to 0.98). There was no significant difference between the two groups in the incidence of minor and major bleeding complications.

Conclusions Our findings showed that compared with AT alone, combined AT and intracoronary GPI treatment resulted in improved myocardial reperfusion, better cardiac function, and MACE-free survival benefits at the long-term follow-up for patients with STEMI undergoing PPCI.

Keywords: Glycoprotein IIb/IIIa inhibitors; Meta-analysis; Myocardial reperfusion; Thrombectomy; Percutaneous coronary intervention

1 Introduction

Primary percutaneous coronary intervention (PPCI), if available, is widely accepted as the most effective reperfusion modality in patients with ST-segment elevation myocardial infarction (STEMI).\[1\] However, one of the limitations of PPCI is the possibility of distal embolization of the thrombus and microvascular obstruction (MVO), which results in suboptimal myocardial reperfusion and increased mortality.\[2–4\] Aspiration thrombectomy (AT) has been considered a simple way to remove the thrombus before stent deployment, thereby improving myocardial reperfusion. However, recent trials have demonstrated a lack of benefit of thrombus aspiration on clinical outcomes and suggested possible harm from an increased risk of stroke.\[5–7\] Furthermore, studies have indicated that AT cannot remove the entire thrombotic mass and many small particles may remain in small arteries, leading to residual thrombus and microemboli in the microvasculature.\[8\] Glycoprotein IIb/IIIa inhibitors (GPI), such as abciximab, eptifibatide, and tirofiban, have been shown to be effective in lowering the thrombus burden and even disaggregating embolized platelet microaggregates; thus, they may play a role in counteracting the potential embolic effect of thrombectomy.\[9,10\] The preferred route of GPI administration is direct intracoronary injection into the infarct related artery as it has been shown to achieve a higher local concentration and further clinical efficacy than standard intravenous administration.\[11–13\]
2 Methods

2.1 Data sources

PubMed, Embase, Web of Science, and CENTRAL databases were searched systematically, as well as the references of eligible studies and recent reviews, for relevant studies published up until December 31, 2016. The keywords and corresponding Medical Subject Headings (Mesh) were as follows: “intracoronary”, “abciximab”, “tirofiban”, “eptifibatide”, “glycoprotein IIb/IIIa inhibitors”, “thrombectomy”, “myocardial infarction”, and “percutaneous coronary intervention”. No limits regarding language were applied.

2.2 Selection criteria

The inclusion criteria were as follows: (1) RCTs involving patients with STEMI undergoing PPCI; (2) trials that compared combined AT and intracoronary GPI (abciximab, tirofiban, or eptifibatide) with AT alone (control); and (3) studies that reported data on any of the outcomes of interest (reported below). The exclusion criteria were: (1) trials using intracoronary administration of GPI combined with other drugs and (2) duplicate reports.

2.3 Data collection and quality assessment

Two independent investigators assessed the studies for eligibility and extracted the following information: the study characteristics, the patient characteristics at baseline, features of the interventions, and the outcomes. Data were managed according to the intention-to-treat principle. In the case of missing or unclear information, we attempted to contact the authors of the original studies by e-mail.

The methodological quality of eligible trials was assessed by two independent reviewers using the criteria of the Cochrane Handbook.[22] All divergences were resolved by discussion with a third reviewer.

2.4 Outcomes and definitions

The outcomes chosen for this meta-analysis were major adverse cardiac events (MACE) at short-term (≤ 1 month) and long-term (6–12 months) follow-up, thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade (TMPG),[3] infarct size (IS) determined by cardiac magnetic resonance, left ventricular ejection fraction (LVEF), and bleeding complications during the hospital stay.

2.5 Statistical analysis

Two investigators cross-checked the data from all the identified studies. The risk ratio (RR) and mean difference (MD), and their corresponding 95% CIs, were calculated for dichotomous or continuous outcome data, respectively. A fixed-effect or random-effects model was chosen according to the presence of statistically significant heterogeneity between studies. Heterogeneity was assessed with the Cochran Q test and the I² statistic (P values < 0.1 and I² values > 50% were considered statistically significant). If the continuous data were reported as the median and interquartile range (IQR), the mean and standard deviation (SD) were estimated using the median and the estimated SD (SD = IQR/1.35).[22] We conducted sensitivity analyses by determining the influence of individual studies on the pooled estimates. A study was considered significantly influential if its exclusion changed the effect estimate by at least 20%.[23] Subgroup analyses for each outcome were performed according to the following criteria: type of GPI (abciximab vs. small-molecule GPI), median ischemic time (symptom onset to catheterization), baseline TIMI flow grade 0/1, left anterior descending occlusion (≤ 50% or > 50%). Funnel plots were used to examine potential publication bias when the number of studies was sufficient.[22] A two-sided P < 0.05 was considered statistically significant. All analyses were conducted using the statistical software RevMan 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and Stata 11.0 (Stata Corp., College Station, Texas, USA). We performed this meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.[24]

3 Results

3.1 Eligible studies

From an initial total of 795 publications (Figure 1), eight RCTs (923 patients) fulfilled the inclusion criteria.[14–21] Abciximab, eptifibatide, and tirofiban were the study drugs in two[14,19] one,[17] and five studies,[15,16,18,20,21] respectively. The patients were administered with aspirin and clopidogrel in all studies except one in which a small number of patients was given prasugrel instead of clopidogrel.[19] The patients received procedural anticoagulation with unfractionated
heparin in all studies but one in which bivalirudin was used as the anticoagulant. The mean age of patients in the individual trials ranged from 52 to 64 years. The majority of the patients were male (68%). The follow-up time reported among trials varied with seven trials reporting short-term outcomes (in-hospital to one month), and four reporting only long-term results (6–12 months). Detailed information regarding the identified trials is provided in Table 1.

According to the Cochrane Collaboration’s risk of bias evaluation tool (Figure 2), six RCTs included in this meta-analysis reported detailed descriptions of appropriate randomization. Only one trial described the allocation concealments in detail. Five studies used blinding of outcome assessment to ensure that observers analyzed the data independently. Most trials had a low risk of bias in incomplete outcome data and selective reporting. No other obvious potential sources of bias were found in any trial.

### 3.2 Effects of interventions

The incidence of MACE at the longest available follow-up was reported in eight studies (Figure 3). No study demonstrated a statistically significant difference in the risk of short-term MACE between GPI and control groups (RR: 0.75, 95% CI 0.38 to 1.50, \(P = 0.42\); heterogeneity: \(I^2 = 0\)). However, intracoronary use of GPI was associated with a significantly reduced risk of MACE at long-term follow-up (RR: 0.60, 95% CI: 0.37 to 0.98, \(P = 0.04\); heterogeneity: \(I^2 = 0\)).

Four studies assessed myocardial reperfusion assessed by TMPG (Figure 4). The pooling analysis showed that intracoronary GPI injection significantly increased the incidence of TMPG compared to controls (RR: 1.15, 95% CI: 1.04 to 1.26, \(P = 0.005\); heterogeneity: \(I^2 = 0\)).

Three studies reported IS assessed by cardiac imaging (Figure 5). Intracoronary GPI was associated with significant reduction in IS compared to controls (MD: \(-3.46, 95\%\ CI: -5.18 to -1.73, P < 0.001\); heterogeneity: \(I^2 = 0\)).

Eight studies assessed LVEF (Figure 6) and results showed that GPI significantly improved LVEF compared to the control group (MD: \(1.44, 95\%\ CI: 0.54 to 2.33, P = 0.002\); heterogeneity: \(I^2 = 34\%).

---

**Table 1**

| Identified through database searching (n = 794) | Additional records identified through other sources (n = 1) |
|------------------------------------------------|----------------------------------------------------------|
| Records identified through database searching (n = 794) | Additional records identified through other sources (n = 1) |
| Records after duplicates removed (n = 358) | Records excluded (n = 322) |
| Full-text articles assessed for eligibility (n = 36) | Full-text articles excluded, with reasons (n = 27): |
| - Not STEMI patients included (n = 1) |
| - Combination of other intracoronary agents (n = 5) |
| - Inappropriate control groups (n = 7) |
| - Lack of relevant outcomes (n = 7) |
| - Non-randomized study (n = 3) |
| - Duplicate publication (n = 4) |
| Studies included in qualitative synthesis (n = 9) | Studies included in quantitative synthesis (meta-analysis) (n = 8) |

**Figure 1. Flow diagram of the review process, according to the PRISMA statement.** STEMI: ST-segment elevation myocardial infarction.
### Table 1. Description of included studies.

| Study         | Year | N     | GPI protocol                                                                 | Inclusion criteria                                                                 | Primary outcome                  | Definition of MACE                           | Definition of bleeding | Follow-up, month | *Age* yrs (%) | Men (%) | *Mean or median ischemic time, h | *Baseline TIMI flow grade 0/1, % | *LAD culprit artery, % |
|---------------|------|-------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------|---------------------------------------------|------------------------|-----------------|----------------|---------|---------------------------------|------------------------|-----------------------|
| Ahn, et al[14] | 2014 | 20/10 | IC bolus of abciximab (0.25 mg/kg)                                            | STEMI < 6 h                                                                        | Index of microcirculatory resistance | Cardiac mortality or nonfatal MI            | NR                     | 1               | 57/63          | 90%/60% | 4.1/5.8                        | 90/100                | 75/70                 |
| Gao, et al[15] | 2016 | 80/80 | IC bolus of tirofiban (10 μg/kg) with a subsequent 48-h IV infusion (0.15 μg/kg per minute) | STEMI < 12 h                                                                      | MACE                             | Cardiac mortality, nonfatal MI, or revascularization | Hemorrhagia and stool occult blood | 6               | 63/64          | 41%/50% | 6.7/5.0                        | 94/93                 | 48/38                 |
| Geng, et al[16] | 2016 | 78/72 | IC bolus of tirofiban (25 μg/kg)                                              | STEMI < 12 h                                                                      | MACE                             | Cardiac mortality, nonfatal MI, or revascularization | Bleeding gums, microscopic hematuria, and epistaxis | 6               | 58/60          | 55%/56% | 1.1/1.2a                      | 96/97                 | 100/100               |
| Iancu, et al[17] | 2012 | 25/25 | IC bolus of eptifibatide (180 μg/kg) with a subsequent 12-h IV infusion (2.0 μg/kg per minute) | STEMI < 12 h                                                                      | Microvascular reperfusion        | Mortality, nonfatal MI, or revascularization | NR                     | 1               | 55/55          | 80%/88% | 4.5/4.7                        | 100/100                | 100/100               |
| Ji, et al[18]  | 2015 | 64/61 | IC bolus of tirofiban (10 μg/kg) with a subsequent IV infusion (0.15 μg/kg per minute) for 12-36 h | STEMI < 12 h                                                                      | Microvascular reperfusion        | Cardiac mortality or nonfatal MI            | TIMI criteria          | 6               | 58/59          | 38%/43% | 2.0/1.9a                      | 100/100                | 47/31                 |
| Stone, et al[19] | 2012 | 118/111 | IC bolus of abciximab (0.25 mg/kg)                                           | STEMI < 4 h                                                                        | Infarct size                     | Mortality, nonfatal MI, stroke, or revascularization | TIMI criteria          | 12              | 60/62          | 71%/77% | 2.4/2.5                        | 75/72                 | 100/100               |
| Wang, et al[20] | 2015 | 72/47 | IC bolus of tirofiban (10 μg/kg) with a subsequent 48-h IV infusion (0.15 μg/kg per minute) | STEMI < 12 h                                                                      | Markers of platelet activation and endothelial dysfunction | Mortality, nonfatal MI, or revascularization | Gastrointestinal bleeding | In-hospital | 57/58          | 71%/75% | NR                             | 100/100                | 49/47                 |
| Zhang, et al[21] | 2014 | 30/30 | IC bolus of tirofiban (25 μg/kg)                                              | STEMI < 12 h                                                                      | Micro-vascular reperfusion       | Mortality, nonfatal MI, or revascularization | Bleeding gums, microscopic hematuria, gastrointestinal bleeding, hemorrhysis, and epistaxis | 1               | 57/60          | 80%/77% | 4.9/5.9                        | 100/100                | 100/100               |

*Data are reported as thrombectomy and GPI/thrombectomy alone; *Time from Symptom to hospital arrival; GPI: glycoprotein IIb/IIIa inhibitors; IC: intracoronary; IV: intravenous; LAD: left anterior descending coronary artery; MACE: major adverse cardiac events; MI: myocardial infarction; NR: not reported; STEMI: ST-segment elevation myocardial infarction; TIMI: thrombolysis in myocardial infarction.

Six studies reported periprocedural bleeding complications (Figure 7). There was no significant difference in minor bleeding complications between GPI and control groups (RR: 1.11, 95% CI: 0.62 to 1.99, P = 0.71; heterogeneity: $P_{het} = 0.91, I^2 = 0$). The risk of TIMI-defined major bleeding was similar in the GPI group and the control group (RR: 5.69, 95% CI: 0.69 to 49.67, P = 0.11; heterogeneity: $P_{het} = 0.87, I^2 = 0$).
NIU XW, et al. Improved myocardial reperfusion by combined thrombectomy and intracoronary GPI

Figure 2. Risk of bias assessment according to the Cochrane Collaboration’s bias tool.

Figure 3. Relative risk of MACE for the combined thrombectomy and intracoronary GPI group versus the thrombectomy alone group at short- and long-term follow-up. MACE: major adverse cardiac events; GPI: glycoprotein IIb/IIIa inhibitors.

Figure 4. Relative risk of TMPG 3 for the combined thrombectomy and intracoronary GPI group versus the thrombectomy alone group. GPI: glycoprotein IIb/IIIa inhibitors; TIMI: thrombolysis in myocardial infarction; TMPG: TIMI myocardial perfusion grade.
Figure 5. Mean difference of in infarct size for the combined thrombectomy and intracoronary GPI group versus the thrombectomy alone group. GPI: glycoprotein IIb/IIIa inhibitors.

Figure 6. Mean difference of LVEF for the combined thrombectomy and intracoronary GPI group versus the thrombectomy alone group. GPI: glycoprotein IIb/IIIa inhibitors; LVEF: left ventricular ejection fraction.

Figure 7. Relative risks of minor and major bleeding for the combined thrombectomy and intracoronary GPI group versus the thrombectomy alone group. GPI: glycoprotein IIb/IIIa inhibitors.

3.3 Sensitivity and subgroup analyses

The sensitivity analyses demonstrated that no single study significantly altered the pooled RR of MACE, TMPG, IS, LVEF, and bleeding complications. The subgroup analyses revealed that type of GPI, ischemic time, baseline TIMI flow grade, and infarct artery lesion location did not significantly influence the RR of the GPI or control group with respect to all of the outcomes mentioned above (all $P_{interaction} > 0.05$) (Table 2).
Table 2. Overall and subgroup analyses for all outcome measures.

|                    | Short-term MACE | Long-term MACE | TMPG | IS | LVEF | Minor bleeding | Major bleeding |
|--------------------|-----------------|----------------|------|----|-----|---------------|---------------|
| Overall analysis   | 0.75 (0.38–1.50) | 0.49 (0.25–0.98) | 1.15 (1.04–1.26) | 1.44 | 1.11 (0.62–1.99) | 5.69 (0.69–46.67) |
| Subgroup analysis  |                 |                |      |    |     |               |               |
| Type of GP IIb/IIIa inhibitors |           |                |      |    |     |               |               |
| Abciximab          | 2.35 (0.47–11.87) | 0.84 (0.33–2.09) | NA   | −3.91 | 1.57 | 0.31 (0.01–7.62) | 4.71 (0.23–96.95) |
| Small-molecule     | 0.54 (0.24–1.21) | 0.27 (0.09–0.81) | 1.15 (1.04–1.26) | −2.90 | 1.42 | (0.45, 2.38) | 1.18 (0.65–2.15) | 6.68 (0.35–126.64) |
| Ischemic time      |                 |                |      |    |     |               |               |
| ≤4 h               | 1.14 (0.33–3.91) | 0.54 (0.26–1.12) | 1.19 (0.99–1.43) | −3.44 | 1.33 | (0.06, 2.59) | 1.18 (0.59–2.35) | 5.69 (0.69–46.67) |
| > 4 h              | 0.27 (0.05–1.62) | 0.25 (0.03–2.19) | 1.12 (1.01–1.25) | −4.00 | 1.22 | (−0.12, 2.55) | 1.00 (0.26–3.84) | NA |
| Proportion of patients with baseline TIMI flow grade 0/1 |           |                |      |    |     |               |               |
| ≤90%               | 2.35 (0.47–11.87) | 0.84 (0.33–2.09) | NA   | −3.90 | 0.80 | 0.31 (0.01–7.62) | 4.71 (0.23–96.95) |
| > 90%              | 0.54 (0.24–1.21) | 0.27 (0.09–0.81) | 1.15 (1.04–1.26) | −2.97 | 1.51 | (0.56, 2.46) | 1.18 (0.65–2.15) | 6.68 (0.35–126.64) |
| Proportion of LAD occlusion |           |                |      |    |     |               |               |
| ≤50%               | 0.78 (0.30–1.99) | 0.22 (0.05–0.98) | 1.19 (0.99–1.43) | −2.90 | 0.85 | (−5.49, −0.31) | 1.35 (0.69–2.66) | 6.68 (0.35–126.64) |
| > 50%              | 0.73 (0.27–2.01) | 0.67 (0.30–1.46) | 1.12 (1.01–1.25) | −3.91 | 2.65 | (1.08, 4.22) | 0.66 (0.21–2.15) | 4.71 (0.23–96.95) |

Treatments were expressed as the risk ratio and mean difference for the dichotomous or continuous outcome data, respectively. IS: infarct size; LAD: left anterior descending; LVEF: left ventricular ejection fraction; MACE: major adverse cardiac events; NA: not applicable; TIMI: thrombolysis in myocardial infarction; TMPG: TIMI myocardial perfusion grade.

3.4 Publication bias

Visual inspection of the funnel plots did not reveal any asymmetry with regard to MACE, LVEF, or bleeding complications.

4 Discussion

In this meta-analysis of eight randomized trials involving 923 patients, we found that compared with aspiration thrombectomy alone, concomitant administration of intracoronary GPI enhanced myocardial perfusion, reduced infarct size, and improved LVEF in patients with STEMI undergoing PCI. Furthermore, GPI use may decrease the risk of long-term MACE. There was no significant difference between the two groups in the incidence of minor and major bleeding complications, suggesting comparable safety.

During PCI, distal embolization of the thrombus and subsequent MVO limit effective myocardial reperfusion and further extend infarction, resulting in a poor prognosis.[2–4]

Adjunctive mechanical and pharmacologic treatments have been proposed to reduce distal embolization and achieve the best myocardial reperfusion after PCI. By further reducing the risk of thrombotic debris embolization and subsequent MVO with myocardial injury, it has been postulated that the combination of mechanical and pharmacologic treatment will enhance myocardial salvage and may improve clinical outcomes in patients with STEMI.[10] A retrospective registry study of 644 patients with STEMI found that the combination of AT with intravenous GPI exerted a synergistic effect on improving myocardial perfusion and clinical outcomes compared with either treatment modality administered separately.[25] A previous meta-analysis pooling the individual data of 2686 patients enrolled in 11 RCTs indicated that the combination of AT and abciximab was associated with a significantly reduced rate of mortality at a median follow-up of one year compared to AT alone [hazard ratio (HR): 0.61, 95% CI: 0.38 to 0.90].[26] Similarly, in a recent individual patient meta-analysis of more than 18000 patients with STEMI, patients treated with both AT and GPI had a lower risk of cardiovascular death within 30 days compared to those receiving AT only [HR: 0.63, 95%CI: 0.44 to 0.88].[27]
These two meta-analyses suggested that concomitant administration of intravenous GPI could enhance the clinical benefits observed with AT. In contrast, in a meta-regression analysis including 17 trials with 20,960 patients, Elgendy et al. found that GPI administration did not modify any association between AT and adverse cardiovascular outcomes (mortality, reinfarction, and the combined outcome of mortality or reinfarction). However, the conflicting results of three meta-analyses may not be definitive given that these were subgroup or meta-regression analyses. Further studies are needed to evaluate whether combined thrombectomy and GPI can exert a synergistic cardioprotection effect during PPCI. For the administration of GPI, intracoronary injection could offer increased local drug concentrations resulting in a more pronounced inhibition of platelet clot aggregation compared to the intravenous route. Furthermore, the locally administered GPI would reach the cellular and molecular target more efficiently after mechanical removal of the thrombus. Indeed, the CICERO trial, which randomized 534 patients with STEMI undergoing primary PCI with AT, has demonstrated that intracoronary administration of abciximab was superior to intravenous administration in improving myocardial reperfusion (reflected by myocardial blush grade) and reducing IS. In a retrospective study exploring the role of AT combined with intracoronary administration of GPI in patients with STEMI, Yan et al. reported that the combination treatment was related with improved myocardial perfusion, saved more myocardium, and resulted in better clinical prognoses. The present study summarized the current available RCTs comparing the combination of AT with intracoronary GPI treatment with AT alone in patients with STEMI undergoing PPCI, with a view to providing more explicit information for use in the clinical setting. TMPG is an angiographic marker of myocardial perfusion. Achievement of TMPG 3 is the important goal of reperfusion therapy, and has shown to be associated with improved clinical outcomes at long-term follow-up. Our meta-analysis found that the improvement in microvascular perfusion in response to the combination treatment was paralleled by an improvement in myocardial salvage, as assessed by IS and LVEF. Additionally, these beneficial effects on surrogate endpoints could translate into a reduced rate of long-term MACE.

Although there were no statistically significant subgroup interactions, we cannot state with certainty whether these specified factors impacted the intervention effect. Our study included the trials of three types of GPI (abciximab, eptifibatide and tirofiban). The different pharmacokinetic and pharmacodynamic features of these drugs may have produced different clinical effects. However, a previous meta-analysis demonstrated that there was no difference in angiographic, electrocardiographic, and clinical outcomes in patients with STEMI using abciximab and small molecule GPI. The ischemic time, preprocedural TIMI flow grade, and location of occlusion are known factors affecting myocardial infarct size. It is plausible that combined intracoronary GPI and thrombectomy treatment would be more effective in patients with the greatest potential for infarct size reduction. However, the small sample size in our meta-analysis did not allow us to draw any definite conclusions. More large-scale RCTs with greater statistical power are required to confirm these observations.

In the 2015 ACC/AHA/SCAI guideline update on PPCI, routine use of AT as an adjunct to PCI is not recommended because AT use did not bring clinical benefit to patients with STEMI but could increase stroke risk. However, there is still a role for AT in selective conditions with heavy thrombus burden or procedural-related thrombotic complications. In the clinical setting, physicians should consider the use of intracoronary GPI to obtain the best myocardial reperfusion for patients with STEMI undergoing PCI with AT.

A major strength of the present study was that this is the first meta-analysis to exclusively compare combined AT and intracoronary GPI treatment with AT alone in a contemporary cohort of patients with STEMI. Our findings offer positive evidence for the improvement of myocardial perfusion after primary PCI, and pave the way for further RCTs to confirm the beneficial role of combined AT and intracoronary GPI treatment in patients with STEMI.

4.1 Study limitations

Our study had several limitations. First, this is a study-level meta-analysis based on the published aggregate patient data. Second, the definition of MACE was not fully consistent across the trials. However, the MACE endpoint usually consisted of mortality, myocardial infarction, and repeat revascularization. In support of this, our analysis of MACE outcomes did not show any evidence of statistical heterogeneity. Additionally, we did not evaluate the individual components of the MACE endpoint because they were reported in a minority of studies only. Third, dose and method of GPI administration were heterogeneous among the included studies. Fourth, some outcomes were applicable for evaluation in only a portion of included studies, which led to wider 95% CI and less conclusive results.

4.2 Conclusions

Our findings showed that thrombectomy combined with...
intra coronary GPI treatment could result in improved myocardial reperfusion, smaller infarcts, and better cardiac function compared to thrombectomy alone. Furthermore, these cardioprotective effects may translate into a MACE-free survival benefit at long-term follow-up for patients with STEMI undergoing PCI. However, additional evidence from large RCTs is warranted to further substantiate these findings, given the limitations of the current available evidence.

References

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13–20.

2. Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002; 23: 1112–1117.

3. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105: 1909–1913.

4. Stone GW, Peterson MA, Lansky AJ, et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002; 39: 591–597.

5. Jolly SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 2015; 372: 1389–1398.

6. Jones DA, Rathod KS, Gallagher S, et al. Manual thrombus aspiration is not associated with reduced mortality in patients treated with primary percutaneous coronary intervention: an observational study of 10,929 patients with ST-segment elevation myocardial infarction from the London Heart Attack Group. JACC Cardiovasc Inter 2015; 8: 575–584.

7. Zhang Y, Peng L, Fan YY, et al. Additional manual thrombus aspiration for ST-segment elevation myocardial infarction during percutaneous coronary intervention: an updated meta-analysis. J Geriatr Cardiol 2016; 13: 344–354.

8. Burzotta F, Trani C, Romagnoli E, et al. A pilot study with a new, rapid-exchange, thrombus-aspirating device in patients with thrombus-containing lesions: the Diver C.E. study. Catheter Cardiovasc Interv 2006; 67: 887–893.

9. De Luca G, Savonitto S, van't Hof AW, et al. Platelet GP IIb-IIIa receptor antagonists in primary angioplasty: back to the future. Drugs 2015; 75: 1229–1253.

10. Hillegass WB, Brott BC. Thromboaspiration and IIb/IIIa therapy in STEMI: abciximab redux? Catheter Cardiovasc Interv 2013; 82: 612–613.

11. Deibele AJ, Jennings LK, Tcheng JE, et al. Intra coronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation 2010; 121: 784–791.

12. Gu YL, Kampinga MA, Wieringa WG, et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 2010; 122: 2709–2717.

13. Fu G, Jia L, Zhao X, et al. A comparison of intracoronary with intravenous glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized controlled trials. J Interv Cardiol 2012; 25: 223–234.

14. Ahn SG, Lee SH, Lee JH, et al. Efficacy of combination treatment with intracoronary abciximab and aspiration thrombectomy on myocardial perfusion in patients with ST-segment elevation myocardial infarction undergoing primary coronary stenting. Yonsei Med J 2014; 55: 606–616.

15. Gao L, Cao Z, Zhang H. Efficacy and safety of thrombectomy combined with intracoronary administration of tirofiban in ST-segment elevation myocardial infarction (STEMI). Med Sci Monit 2016; 22: 2699–2705.

16. Geng T, Zhang JG, Song ZY, et al. Aspiration thrombectomy and intracoronary tirofiban in ST-segment elevation myocardial infarction Combination treatment for patients undergoing primary percutaneous coronary intervention. Herz 2016; 41: 732–739.

17. Iancu A, Ober C, Bondor CI, et al. Microvascular effect of intracoronary eptifibatide in acute myocardial infarction. Cardiology 2012; 123: 46–53.

18. Ji ZG, Liu HB, Liu ZH, et al. Influence of Tirofiban maintenance duration on patients with acute myocardial infarction treated by percutaneous coronary intervention. Chronic Dis Transl Med 2015; 1: 81–88.

19. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012; 307: 1817–1826.

20. Wang K, Zuo G, Zheng L, et al. Effects of tirofiban on platelet activation and endothelial function in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cell Biochem Biophys 2015; 71: 135–142.

21. Zhang D, Wang L, Du J, et al. Effect of intracoronary tirofiban combined with nitroprusside injection through thrombus aspiration catheter during primary percutaneous coronary intervention on acute anterior myocardial infarction patients with heavy thrombosis burden. Zhonghua xin xue guan bing za zhi 2014; 42: 25–30.

22. Higgins J. Green S. Cochrane handbook for systematic reviews
of interventions version 5.1.0. The Cochrane Collaboration, 2011. http://www.handbook.cochrane.org (accessed March 7, 2017).

23 Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011; 58: 1569–1577.

24 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339.

25 Pyxaras SA, Mangiacapra F, Verhamme K, et al. Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention. Catheter Cardiovasc Interv 2013; 82: 604–611.

26 Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J 2009; 30: 2193–2203.

27 Jolly SS, James S, Dzavik V, et al. Thrombus aspiration in ST-segment elevation myocardial infarction: an individual patient meta-analysis: Thrombectomy Trialists Collaboration. Circulation 2017; 135: 143–152.

28 Elgendy IY, Huo T, Bhatt DL, et al. Is aspiration thrombectomy beneficial in patients undergoing primary percutaneous coronary intervention? Meta-analysis of randomized trials. Circ Cardiovasc Interv 2015; 8: e002258.

29 Yan HB, Li SY, Song L, et al. Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction. Chin Med J (Engl) 2010; 123: 877–883.

30 Sattur S, Sarwar B, Sacchi TJ, et al. Correlation between markers of reperfusion and mortality in ST-elevation myocardial infarction: a systematic review. J Invasive Cardiol 2014; 26: 587–595.

31 De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol 2009; 53: 1668–1673.

32 Stone GW, Witzenbichler B, Godlewski J, et al. Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction one-year results from the INFUSE-AMI trial. Circ Cardiovasc Interv 2013; 6: 527–534.

33 Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2016; 67: 1235–1250.